PharmaShots | Incisive News in 3 Shots

Subscribe Now

Lynparza

AstraZeneca and Merck Receive EC’s Approval of Lynparza (olaparib) for Metastatic Castration-Resistant Prostate Cancer

AstraZeneca and Merck Receive EC’s Approval of Lynparza (olaparib) for Metastatic Castration-Resistant Prostate Cancer

December 21, 2022

AstraZeneca and MSD's Lynparza (Olaparib) Receives the CHMP's Positive Opinion as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

AstraZeneca and MSD's Lynparza (Olaparib) Receives the CHMP's Positive Opinion as 1L Maintenance Treatment for HRD-Positive Advanc...

September 21, 2020

AstraZeneca and MSD Report Five Year Data of Lynparza in P-III SOLO-1 Study for 1L Maintenance Treatment in Patients with BRCA-Mutated Ovarian Cancer

AstraZeneca and MSD Report Five Year Data of Lynparza in P-III SOLO-1 Study for 1L Maintenance Treatment in Patients with BRCA-Mut...

September 18, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us